Revita , scientific and clinical evidence
®
Revita is an intact human placental membrane allograft that preserves all layers of the biologic tissue and maintains the physiologic 3D architecture of the natural barrier membrane.
Intact Human Placental Membrane vs. Dehydrated Competitor
Revita preserves all three layers of the amniotic membrane architecture.
Unprocessed placental membrane
Revita preservation of 3D architecture
Competitor
Revita provides the complete intact human placental membrane that is the physiologic tissue carrier naturally found in the body.
This complete membrane containing amnion, intermediate layer and chorion retains many of the cytokines and growth factors the body uses to heal, protect and grow tissues.
CLINICAL APPLICATIONS INCLUDE:
Wound Care
-
Diabetic Wounds
-
Venous / Arterial Ulcers
-
Pressure Ulcers
-
Burn Wounds
-
Plastic Surgery
PRESERVATION OF THE INTERMEDIATE LAYER
The amniotic intermediate layer is a vital part of the membrane barrier present between the amnion and chorion layers
THE INTERMEDIATE LAYER:
-
Acts as a cushion
-
Contains Hyaluronic Acid (HA) + Collagen
-
Contains growth factors
-
Contains Glycosaminoglycans and Proteoglycans
CASE STUDY - Revita Clinical Application: Challenging Chronic Wound
®
Day 0 Wound
Day 0 Application
Day 41
95% Closure
Introduction
The patient in this case study was selected to evaluate this exceptional product capacity in a notably challenging clinical application. The patient, an elderly woman with multiple comorbidities and existing amputations, presented with a deep venous leg ulcer that consistently failed other treatments. Her case is presented here.
Initial Patient Evaluation and Product Application: Day 0
87-year-old female presented with a severe venous leg ulcer (VLU) on her lower right leg measuring 11 cm in length and 4 cm in width with exposed tendon and heavy exudate of purulent consistency. Conservative therapies were previously attempted for months without success.
The patient had a history of diabetes and smoking, and all toes had previously been amputated. She also reported a high pain level of 8 on a Visual Analog Scale (VAS) of 1 to 10 at the site of the VLU.
At the time of initial evaluation, the wound was cleaned and five Revita allografts were used to cover the wound.
Standard facility protocol for tissue application was followed, including placement of a non-adherent hydrogel for protection. Clinicians rated the ease of Revita application as excellent.
Follow Up: Day 27
The wound was cleaned, debrided, and clinicians re-applied five Revita allografts. Clinicians rated the ease of Revita application as excellent.
Follow Up: Day 41
Clinicians noted “good results” with healthy tissue developing around the previously exposed tendon. The wound was cleaned, debrided, and clinicians re-applied four Revita allografts.
Final Treatment: Day 62
Clinicians noted a “considerable improvement” with low exudate levels and healthy tissue development and reapplied three Revita allografts to continue treatment.
Wound Resolution
Wound continued to progress through to closure with “incredible results” noted by the clinicians.